ROCKVILLE, Md .– (COMMERCIAL LINE) – The announcement of a recent investment by Semler Scientific (SMLR) in SYNAPS Dx (SDx), a private company focused on the research, development and commercialization of diagnostic tools for neurodegenerative diseases and conditions, including Alzheimer’s disease ( AD), further positions DISCERN ™ as a diagnostic for early AD. In the fourth quarter and YTD 2021 financial results, SMLR said: “SMLR had previously announced its fall 2020 investment in another private company, now known as SDx, whose product is a test for the first AD. , called DISCERN. SMLR believes that its current products and services, and any future products or services it may offer, position it to provide valuable information to its customer base, which in turn enables them to better guide patient care. ”
Frank Amato, CEO and President of SDx, says, “We believe this investment continues to distinguish the accuracy of our biomarkers from all other diagnostic tools in AD. DISCERN ™ is the first accurate, autopsy-confirmed, minimally invasive test for definitive AD diagnosis compared to other forms of dementia and confirms its value as the most promising breakthrough for early AD diagnosis. SDx identified a significant need for the DISCERN test based on strong adoption of the test during a limited test launch and market receptivity to its clinical utility study documenting a clear and unmet need for a simple and highly accurate mode to identify early AD patients in disease and facing concomitant dementias “.
DISCERN is based on three independently accurate biomarkers related to synaptic function and is well positioned to help address a number of key issues that payers, providers and patients face when it comes to obtaining a definitive diagnosis for AD all. beginning of the patient’s journey.
Amato explains: “DISCERN is now on track to help reduce the burden of AD diagnosis on patients and their families, physicians and the health system in general. By calling for a simpler, more definitive approach to early-stage AD identification at all-time highs, this non-invasive test reinforces the company’s focus on supporting management therapeutic decisions that are most convenient for people living with the ‘TO”.
SDx and DISCERN have achieved important milestones which include:
DISCERN is the first AD test of its kind to obtain the 206U and 207U code of the proprietary laboratory tests (PLA). These codes and related reimbursements position DISCERN as a critical and essential component of patient-centered and value-based strategies for suppliers and payers, providing the code needed for reimbursement.
DISCERN received the revolutionary designation from the Food & Drug Administration.
In October 2021, SDx announced the closure of its $ 10 million Series A investment, including private equity, individual and family funds, and corporate investors. The proceeds will be used to increase production and meet market demand for DISCERN.
In December 2021, the Company announced the creation of an advisory board comprised of leaders in healthcare innovation: Michael Gorton, founding CEO, Teladoc and CEO, Recuro Health, Wayne Jenkins, MD, MPH, medical executive, Frederick Huie, MD, general surgeon in New York, New York and Dave Rosa, president and CEO, NeuroOne Medical Technologies Corporation.
To further promote DISCERN’s strategic positioning and commercialization, SDx maintained Outcome Capital to explore investment, collaboration and distribution partner opportunities. Outcome Capital is a highly specialized life science and healthcare consulting and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers and acquisitions, partnerships and corporate finance. The company leverages its proven “strategy-driven execution” approach to increase value by assisting management teams and their boards in navigating the financial and corporate markets and implementing the best path to success.
About SYNAPS Dx
SYNAPS Dx is a privately held company focused on the research, development and commercialization of diagnostic tools for neurological disorders and conditions, including Alzheimer’s disease. The company offers DISCERN ™, the first accurate and minimally invasive test for the definitive diagnosis of Alzheimer’s disease (AD) compared to other forms of dementia. The SYNAPS Dx laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform highly complex clinical laboratory tests. If you are a doctor or patient looking for more information on the DISCERN ™ test, please visit https://discerntest.com/. For more information on the Company, please visit https://www.synapsdx.com/. Contact: firstname.lastname@example.org.